Global Nuclear Medicine Market to grow by 10.07% CARG over 2018-2023

November 12, 2019


According to research report titled ‘Global Nuclear Medicine Market: Analysis By Product Type (Diagnostic, Therapeutic), By Diagnostic Nuclear Medicine Type, By Therapeutic Nuclear Medicine Type, By Indication, By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023) - By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, France, Germany, India, China, Japan, Brazil)’ available with Market Study Report LLC, the global nuclear medicine market is estimated to grow with a CARG of 10.07% from 2018 to 2023.
 

For the record, nuclear medicine is a branch of healthcare that uses radioactive substances for research, diagnosis and treatment of diseases. Rising occurrences of cancer, growing number of nuclear centers across globe, coupled with advancements in treatment and medical equipment are propelling the growth of nuclear medicine market. 
 

Based on type of diagnostic applied, nuclear medicine market is divided into PET and SPECT. While on the basis of therapeutics, the industry is segmented as beta emitters, alpha emitters, and brachytherapy. Considering the indication type, nuclear medicine market is categorized as oncological disorders, cardiovascular disorders, neurological disorders, and others, oncological disorders segment is presumed to register significant growth over the forecast period.
 

In terms of geographical landscape, the global nuclear medicine market is fragmented into Europe, North America, Europe, APAC, and rest of world. As of 2018, North America held the largest regional share in the global nuclear medicine market, owing to increasing prevalence of chronic diseases in tandem with advanced medical infrastructure and supportive government regulation, cites the report.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/1550838/
 

According to the research report, the major players in the global nuclear medicine market are Lantheus Holding, Bracco Imaging, Jubilant Lifesciences, Curium, Eckert & Zeigler, and 3B Pharmaceutical Cardinal Health Advanced Accelerator Application.
 

Notably, the research report covers and analyzes the potential growth prospects prevailing in global nuclear medicine market. It offers important statistics on the revenue shares of the current market segments. Besides, the study also identifies and analyzes emerging trends in the nuclear medicine segment, along with major drivers, challenges and opportunities.


Frequently Asked Questions (FAQ) :

Rising occurrences of cancer, growing number of nuclear centers across globe, coupled with advancements in treatment and medical equipment are propelling the growth of nuclear medicine market.
Based on type of diagnostic applied, nuclear medicine market is divided into PET and SPECT. While on the basis of therapeutics, the industry is segmented as beta emitters, alpha emitters, and brachytherapy. Considering the indication type, nuclear medicine market is categorized as oncological disorders, cardiovascular disorders, neurological disorders, and others.
As of 2018, North America held the largest regional share in the global nuclear medicine market, owing to increasing prevalence of chronic diseases in tandem with advanced medical infrastructure and supportive government regulation.
The major players constituting the competitive landscape of nuclear medicine market are Lantheus Holding, Bracco Imaging, Jubilant Lifesciences, Curium, Eckert & Zeigler and 3B Pharmaceutical Cardinal Health Advanced Accelerator Application.